New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareFOXO4-DRI vs Pal-GHK

FOXO4-DRI vs Pal-GHK

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
FOXO4-DRI
Skin & CosmeticAnti-Aging & Longevity
Pal-GHK
Summary
FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
Half-Life
Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
Extended (lipid depot in stratum corneum)
Admin Route
Subcutaneous, Intraperitoneal (research)
Topical
Research
Typical Dose
5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
0.005–0.1% in formulation
Frequency
3 consecutive days per cycle
Once or twice daily
Key Benefits
  • Selectively clears senescent cells (senolytics)
  • Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
  • Demonstrated restoration of physical fitness in aged mice
  • May improve healthspan and reduce age-related tissue dysfunction
  • Potential for treatment of age-related pathologies driven by cellular senescence
  • Does not affect healthy non-senescent cells at therapeutic doses
  • Stimulates collagen I and III synthesis in dermis
  • Reduces the appearance of fine lines and wrinkles
  • Improves skin elasticity and firmness
  • Inhibits collagenase (MMP-1) to preserve existing collagen
  • Enhances wound healing and skin repair
  • Well-tolerated in anti-aging serums and creams
Side Effects
  • Limited human data; largely preclinical evidence
  • Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
  • Weight loss observed at high doses in rodent studies
  • Unknown long-term safety profile in humans
  • Generally very well-tolerated
  • Rare skin irritation at very high concentrations
  • Possible formulation-dependent comedogenicity
Stacks With